Dr. Jean-Martin Beaulieu

Dr. Beaulieu’s lab bridges molecular signaling discoveries with genetic risk insights, shaping therapeutic development for severe psychiatric illness.

Dr. Jean-Martin Beaulieu is a neuroscientist whose research examines how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for psychiatric disorders such as schizophrenia, depression, and bipolar disorder. A pioneer in uncovering the role of beta-arrestin signaling in D2 dopamine receptor function, his work has revealed how mood stabilizers and antipsychotics engage overlapping pathways to influence brain activity. His lab integrates basic and translational approaches, collaborating with geneticists to link molecular mechanisms to human risk factors identified in GWAS, and partnering with industry to develop new therapeutics. Dr. Beaulieu earned his Ph.D. from McGill University, completed postdoctoral training at Duke University, and previously served as a Canada Research Chair at Laval University.